Kremer N, et al. - Researchers sought to systematically review the current literature regarding the use of rituximab and omalizumab for the treatment of bullous pemphigoid (BP) and assess their safety and efficacy. The data suggested similar safety profiles of rituximab and omalizumabare and provided clinical benefit for patients with BP. Compared to omalizumab, lower recurrence rates and a longer time until recurrence were resulted by rituximab. For rituximab and omalizumab, complete response rates were 85% and 84%, respectively.